A stratified model for health outcomes in ankylosing spondylitis by Machado, P et al.
Extended report
Machado P, Landewé R, Braun J, et al. Ann Rheum Dis (2011). doi:10.1136/ard.2011.150037 1 of 7
Accepted 11 June 2011
 ABSTRACT  
 Objective  To investigate the relationships between 
several health outcomes in ankylosing spondylitis (AS). 
 Methods  Baseline pretreatment data from 214 patients 
with AS participating in the AS Study for the Evaluation 
of Recombinant Infl iximab Therapy were analysed. 
Measures of health-related quality of life (HRQoL) and 
physical function were used as dependent variables 
in linear regression analysis. Associations between 
HRQoL (36-Item Short Form (SF-36)), physical function, 
clinical disease activity, spinal mobility, structural 
damage, MRI infl ammation, disease duration, age, 
gender, body mass index and HLA-B27 were explored. 
Univariate associations were retested in multivariate 
models. The robustness of the models was evaluated by 
sensitivity analyses. 
 Results  The physical component of SF-36 was 
independently associated with measures of physical 
function and disease activity (adjusted R 2 (adjR 2 )=
0.39–0.40). The mental component of SF-36 was 
independently associated with physical function 
(adjR 2 =0.07). Physical function was independently 
associated with measures of spinal mobility and 
disease activity (adjR 2 =0.39–0.45). Spinal mobility 
was hierarchically shown to be an intermediate variable 
between structural damage and physical function, while 
physical function was shown to be intermediate between 
spinal mobility and the physical component of SF-36. 
 Conclusion  According to the proposed stratifi ed model 
for health outcomes in AS, HRQoL is determined by 
physical function and disease activity, physical function 
is determined by spinal mobility and disease activity, and 
spinal mobility is determined by structural damage and 
infl ammation of the spine. As more is learnt about how 
to measure AS, knowledge about the disease improves 
and better decisions can be made on the assessment 
and treatment of this disease. 
 INTRODUCTION 
 Health outcomes include different aspects of health 
and illness and their consequences on a person’s 
life. These include health status (symptom sever-
ity and degree of functional limitation), impairment 
(alteration of normal body structure or biofunction), 
quality of life (subjective appraisal of health status), 
costs (monetary costs of obtaining care and costs of 
lost work productivity) and mortality. 1 
 The Assessment of SpondyloArthritis interna-
tional Society (ASAS) has recommended a core 
set of validated ankylosing spondylitis (AS) mea-
sures of impairment and health status to be used in 
clinical trials and clinical practice. 2 – 4 Measurement 
instruments for radiographic damage 5  6 and for 
MRI infl ammation 7  8 have also been developed 
and, recently, a new index for measuring disease 
activity—the AS Disease Activity Score (ASDAS)—
was proposed and validated in AS. 9 – 11 
 The spectrum of AS is heterogeneous and the 
relationships between health outcomes are com-
plex and incompletely understood. Presumably, 
there is a generic hierarchical order of domains, 
with health-related quality of life (HRQoL) at the 
top and signs and symptoms (and MRI infl amma-
tion) at the bottom. HRQoL can be thought of as 
the highest multidimensional goal dependent on 
other domains (eg, health status and impairment), 
refl ecting the overall impact of the illness (including 
signs and symptoms) and its treatment on patients 
and their response to these impacts. However, we 
do not know exactly how these domains inter-
relate. Improved understanding about these rela-
tionships will deepen our knowledge of AS and 
its management, treatment and impact on patients 
and society. 
 This theoretical concept is not new to rheumatic 
diseases (or to most chronic diseases), and goes 
back to the writings of Tennant 12 and Fries 13 and to 
what was to become the International Classifi cation 
of Impairments, Disabilities, and Handicaps of 
the World Health Organization. In this schema, 
as described by Tennant, 12 disease gives rise to 
impairment, defi ned as ‘any loss or abnormality of 
psychological, physiological, or anatomical struc-
ture or function’; impairment itself may lead to 
disability, defi ned as ‘any restriction or lack of abil-
ity to perform an activity in the manner or within 
the range considered normal for a human being’; 
impairments and disabilities, by interacting with 
the physical and social environment, can result in 
handicap, defi ned as a ‘disadvantage for the given 
individual that limits or prevents the fulfi lment of a 
role that is normal’; and at the end of the disease–
handicap continuum we can fi nd quality of life, a 
broader outcome that can be infl uenced by a whole 
series of other factors such as self-esteem, coping 
skills, age, gender and ethnicity. 12 
 Despite being a conceptual frame shared 
between several chronic diseases, the evidence for 
AS is lacking as the number of previous reports 
analysing the relationship between outcomes is 
small, they included small numbers of patients and 
focused on a limited number of outcomes. A more 
broad analysis—adjusting for potential confound-
ers and including a large number of health out-
comes  simultaneously—is lacking, and is of utmost 
importance as it may offer a more solid concep-
tual basis for thinking about outcomes in AS and 
for understanding what we are measuring when 
assessing patients with this disease. In particular, 
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the availability of infl ammation assessed on MRI of the spine 
in a large number of patients is a unique feature of the current 
dataset. 
 In this study we investigated the relationships between 
HRQoL, physical function, disease activity, spinal mobility and 
structural damage in detail and propose a stratifi ed model for 
health outcomes in AS. 
 METHODS 
 AS patient population 
 This study investigated a representative baseline 80% ran-
dom sample (224 patients) of the AS Study for the Evaluation 
of Recombinant Infl iximab Therapy (ASSERT) cohort. 14 Ten 
patients were excluded from the analysis owing to incomplete 
radiographic assessment (n=7), incomplete MRI assessment 
(n=1) or both (n=2). The fi nal number of patients included in 
this study was 214. 
 In brief, ASSERT was a double-blind placebo-controlled clini-
cal trial with infl iximab that included patients with AS (according 
to the modifi ed New York criteria) 15 for at least 3 months prior 
to screening, with a Bath AS Disease Activity Index (BASDAI) 
≥4 (range 0–10) and a Spinal Pain Assessment Score ≥4 (range 
0–10 cm, visual analogue scale). Detailed inclusion and exclu-
sion criteria of patients in the ASSERT trial have been described 
previously. 14 
 Measures of health outcomes 
 Two patient-reported outcomes were used as measures of HRQoL 
and physical function: the 36-Item Short Form (SF-36) health 
survey questionnaire 16 (both the SF-36 Physical Component 
Summary Score (SF-36 PCS) and the SF-36 Mental Component 
Summary Score (SF-36 MCS)) and the Bath AS Functional Index 
(BASFI). 17 It should be noted that, although often mislabelled 
as a quality of life measure, the SF-36 is in fact a health status 
measure and it should be interpreted as such when we use the 
term HRQoL. 
 The BASDAI, 18 the ASDAS 9 – 11 and the level of C-reactive pro-
tein (CRP) were included as measures of clinical disease activity. 
Spinal mobility was assessed using the Bath AS Metrology Index 
(BASMI), 19 – 21 structural damage was assessed by the modifi ed 
Stoke AS Spine Score (mSASSS) 5  6 and MRI spinal infl amma-
tion was assessed by the AS spinal MRI Activity (ASspiMRI-a) 
score. 7  8 All these measurement tools have been validated and 
are recommended for use in AS. 4  22 A more detailed descrip-
tion of these well-known outcome measures can be found in the 
online supplement. 
 Statistical analysis 
 All data are expressed as median (IQR) or proportion if appli-
cable. Pearson (normally distributed variables) and Spearman 
correlation coeffi cients (not normally distributed variables) 
were used to build a correlation matrix between health 
outcomes. 
 Possible associations between BASFI, SF-36 (physical and 
mental component scores) and a large number of outcome mea-
sures (ASDAS, BASDAI, CRP, BASMI, mSASSS, ASspiMRI-a) 
and clinical-demographic variables (disease duration, age, gen-
der, body mass index (BMI) and HLA-B27) were fi rst explored 
by univariate linear regression analysis (using SF36-PCS, SF-36 
MCS and BASFI as dependent variables). Variables with univari-
ate associations with a p value <0.10 were retested in multivari-
ate models. By default, all multivariate models were adjusted for 
disease duration, age, BMI and gender. 
 Separate multivariate models were run using either ASDAS 
or BASDAI as independent variables (as they represent the 
same health outcome), and using either mSASSS or BASMI (to 
avoid collinearity and because we wanted to test if BASMI is an 
intermediate variable between mSASSS and BASFI). A similar 
approach (and for the same reasons) was used for BASMI or 
BASFI as the regressors. 
 As measures of the strength of the relationship between the 
models and the dependent variable, we used the R-square (R 2 ) 
value (the coeffi cient of determination), which is the squared 
value of the multiple correlation coeffi cient (R) and shows how 
much variation in the dependent variable is explained by the 
model. As a further measure of the strength of the model fi t, we 
used the adjusted R-square (adjR 2 ) value, which compensates 
for model complexity providing a fairer comparison of multi-
variate model performance. 
 Non-normally distributed variables (mSASSS, ASspiMRI-a 
score, CRP and disease duration) underwent a normalisation pro-
cedure based on rank order using the van der Waerden technique 
before being entered into the linear regression analysis. All tests 
were two-sided and p values <0.05 were considered statistically 
signifi cant. Analyses were performed using SPSS Version 16. 
 RESULTS 
 Baseline characteristics of the study population 
 Table S2 in the online supplement shows the baseline charac-
teristics of the study population. The study population was 
typical of patients with moderate to severe AS, with poor 
physical function (median BASFI 5.7), high disease activity 
(median BASDAI 6.5 and median ASDAS 4.0) and substan-
tial impairment of spinal mobility (median BASMI 4.6). The 
median SF-36 PCS score (29.5) was well below that of the 
general population of the USA and Europe (range 49.7–52.7). 23 
However, the median SF-36 MCS score (47.1) was in the lower 
range of that of the general population of the USA and Europe 
(range 47.6–54.0). 23 
 Correlation matrix for health outcomes 
 Table 1 presents a correlation matrix for all health outcomes 
in our population. SF-36 MCS correlated weakly with BASFI 
(r=−0.28), BASDAI (r=−0.25) and ASDAS (r=−0.13). SF-36 PCS 
correlated moderately well with BASFI (r=−0.58), BASDAI 
(r=−0.47), ASDAS (r=−0.40) and weakly with BASMI (r=−0.20). 
BASFI correlated moderately well with BASDAI (r=0.45), ASDAS 
(r=0.38), BASMI (r=0.42) and weakly with mSASSS (r=0.18). 
BASMI correlated moderately well with mSASSS (r=0.59) and 
weakly with ASspiMRI-a (r=0.30). 
 Univariate associations between BASFI, SF-36 PCS, SF-36 MCS 
and other outcome measures and clinical-demographic variables 
 Table 2 shows the results of univariate linear regression analysis 
using physical function and HRQoL (physical and mental com-
ponents) as dependent variables: 
BASFI was positively associated with ASDAS (R 1. 2 =0.15), 
BASDAI (R 2 =0.20), BASMI (R 2 =0.18), mSASSS (R 2 =0.040), 
age (R 2 =0.038) and BMI (R 2 =0.064). 
 SF-36 PCS was negatively associated with BASFI (R 2. 2 =0.33), 
ASDAS (R 2 =0.16), BASDAI (R 2 =0.22), BASMI (R 2 =0.038) 
and age (R 2 =0.037), and positively associated with male 
gender (R 2 =0.034). 
 SF-36 MCS was negatively associated with BASFI 3. 
(R 2 =0.076), ASDAS (R 2 =0.018), BASDAI (R 2 =0.064) and 
BMI (R 2 =0.039). 
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 Multivariate linear regression analysis for BASFI, SF-36 PCS 
and SF-36 MCS 
 Independent associations with BASFI, SF-36 PCS and SF-36 MCS 
were explored using multivariate linear regression analysis. By 
default, all models were adjusted for disease duration, age, BMI 
and gender. The results are presented in  tables 3 – 5 and sum-
marised below: 
 BASFI was independently associated with BASMI and with 1. 
measures of clinical disease activity (ASDAS or BASDAI) 
( table 3 ,  m odels 1 and 2). If BASMI and mSASSS were 
forced into the same model as regressors simultaneously, 
the mSASSS contribution did not reach statistical signifi -
cance owing to collinearity (data not shown). 
 When BASMI was replaced by mSASSS in the BASFI 2. 
models ( table 3 , m odels 3 and 4), both ASDAS/BASDAI 
and mSASSS were independently associated with BASFI, 
suggesting that BASMI is hierarchically an intermediate 
variable between mSASSS and BASFI. This is supported 
by the improved fi t in the model with BASFI when 
BASMI (adjR 2 =0.39–0.45) is used instead of mSASSS 
 Table 1  Correlation matrix between health outcomes in ankylosing spondylitis 
   SF-36 MCS  SF-36 PCS  BASFI  BASDAI  ASDAS  BASMI  mSASSS  ASspiMRI-a 
SF-36 MCS r 1 −0.01 −0.28 −0.25 −0.13 −0.07 0.04 0.08
p Value NA 0.88  <0.001  <0.001 0.051 0.279 0.596 0.255
SF-36 PCS r  1 −0.58 −0.47 −0.40 −0.20 −0.10 0.13
p Value  NA  <0.001  <0.001  <0.001  0.004 0.154 0.051
BASFI r   1 0.45 0.38 0.42 0.18 0.04
p Value   NA  <0.001  <0.001  <0.001  0.008 0.535
BASDAI r    1 0.68 −0.03 −0.13 −0.12
p Value    NA  <0.001 0.631 0.064 0.079
ASDAS r     1 0.11 0.11 0.14
p Value     NA 0.103 0.127  0.045 
BASMI r      1 0.59 0.30
p Value      NA  <0.001  <0.001 
mSASSS r       1 0.38
p Value       NA  <0.001 
ASspiMRI-a r        1
p Value        NA
 p Values <0.05 are highlighted in bold. 
 ASDAS, Ankylosing Spondylitis Disease Activity Score; ASspiMRI-a, Ankylosing Spondylitis spinal MRI activity; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; 
BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, linear defi nition of the Bath Ankylosing Spondylitis Metrology Index; mSASSS, modifi ed Stoke Ankylosing Spondylitis 
Spine Score; SF-36 PCS, SF-36 Physical Component Summary Score; SF-36 MCS, SF-36 Mental Component Summary Score. 
 Table 2  Associations between BASFI, SF-36 PCS and SF-36 MCS (dependent variables) and other outcome measures and clinical-demographic 
variables (univariate linear regression analyses) 
 
 BASFI  SF-36 PCS  SF-36 MCS 
 B (95% CI)  β  R  2   p Value  B (95% CI)  β  R  2   p Value  B (95% CI)  β  R  2   p Value 
BASFI NA NA NA NA −2.198 
(−2.620 to −1.776)
−0.576 0.332  <0.001 −1.565 
(−2.303 to −0.828)
−0.276 0.076  <0.001 
ASDAS 0.861 
(0.581 to 1.141)
0.384 0.148  <0.001 −3.383 
(−4.445 to −2.321)





0.450 0.203  <0.001 −2.249 
(−2.817 to −1.680)
−0.472 0.223  <0.001 −1.796 
(−2.723 to −0.869)
−0.254 0.064  <0.001 
CRP 0.194 
(−0.076 to 0.464)
0.097 0.009 0.158 −0.857 
(−1.884 to 0.170)





0.423 0.179  <0.001 −0.915 
(−1.535 to −0.295)





0.199 0.040  0.003 −0.826 
(−1.825 to 0.172)





0.059 0.004 0.387 0.791 
(−0.248 to 1.830)







−0.084 0.002 0.528 0.050 
(−0.953 to 1.052)





0.196 0.038  0.004 −0.140 
(−0.237 to −0.043)







−0.074 0.006 0.279 3.220 
(0.880 to 5.559)





0.253 0.064  <0.001 −0.191 
(−0.433 to 0.050)
−0.107 0.011 0.120 −0.527 
(−0.881 to −0.173)
−0.198 0.039  0.004 
HLA-B27+ 0.238 
(−0.607 to 1.083)
0.038 0.001 0.580 −0.172 
(−3.397 to 3.053)
−0.007 0.001 0.916 −1.976 
(−6.756 to 2.805)
−0.056 0.003 0.416
 p Values <0.05 are highlighted in bold. 
 ASDAS, Ankylosing Spondylitis Disease Activity Score; ASspiMRI-a, Ankylosing Spondylitis spinal MRI activity; B, regression coeffi cient; β, standardised coeffi cient; BASDAI, Bath 
Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, linear defi nition of the Bath Ankylosing Spondylitis Metrology Index; 
BMI, Body Mass Index; CRP, C-reactive protein; mSASSS, modifi ed Stoke Ankylosing Spondylitis Spine Score; R 2 , an estimate of the proportion of variance in the dependent variable 
accounted for by the regression; SF-36 PCS, SF-36 Physical Component Summary Score; SF-36 MCS, SF-36 Mental Component Summary Score; NA, not applicable. 
 group.bmj.com on August 16, 2011 - Published by ard.bmj.comDownloaded from 
Extended report












































































































































































































































































































































































































































































































































































































































































































 2  =
0.
31


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 2  =
0.
30







































































































































































































































































   
 group.bmj.com on August 16, 2011 - Published by ard.bmj.comDownloaded from 
Extended report
Machado P, Landewé R, Braun J, et al. Ann Rheum Dis (2011). doi:10.1136/ard.2011.150037 5 of 7
(adjR 2 =0.26–0.31) in otherwise similar multivariate 
 models ( table 3 ). 
 SF-36 PCS was independently determined by BASFI and by 3. 
measures of clinical disease activity (ASDAS or BASDAI) 
( table 4 , m odels 1 and 2). If BASFI and BASMI were forced 
into the same model as regressors simultaneously, the con-
tribution of BASMI was not statistically signifi cant (col-
linearity, data not shown). 
 When BASFI was replaced by BASMI in the SF-36 PCS 4. 
models ( table 4 , m odels 3 and 4), both ASDAS/BASDAI 
and BASMI were independently associated with SF-36 PCS, 
suggesting that BASFI is hierarchically an intermediate vari-
able between BASMI and SF-36 PCS. This is supported by 
the improved fi t in the model with SF-36 PCS when BASFI 
(adjR 2 =0.39–0.40) is used instead of BASMI (adjR 2 =0.25–
0.30) in otherwise similar multivariate models ( table 4 ). 
 SF-36 MCS was independently determined by BASFI when 5. 
ASDAS was used as an independent variable (ASDAS 
lost statistical signifi cance in this model,  table 5 ,  m odel 
1), and by disease activity when BASDAI was used as an 
independent variable (BASFI lost statistical signifi cance in 
this model,  table 5 , m odel 2). When BASFI was excluded 
from the models, ASDAS was also independently associ-
ated with SF-36 MCS ( table 5 , m odel 3: r=−1.82, p=0.035), 
similarly to BASDAI ( table 5 , m odel 4: r=−1.74, p<0.001). 
Overall, the robustness of the models was lower for SF-36 
MCS (adjR 2 =0.07–0.10) compared with SF-36 PCS and 
BASFI models. 
 An increase of 1 unit in BASMI leads to an estimated aver-6. 
age increase of 0.49 in BASFI independent of the effect of 
ASDAS; similarly, an increase of 1 unit in ASDAS leads to 
an increase of 0.81 in BASFI ( table 3 ). An increase of 1 unit 
in BASFI leads to a decrease of 1.7 in SF-36 PCS ( table 4 ) 
and to a decrease of 1.2 in SF-36 MCS ( table 5 ), indepen-
dent of the effect of ASDAS; similarly, an increase of 1 unit 
in ASDAS leads to a decrease of 2.0 units in SF-36 PCS 
( table 4 ). 
 DISCUSSION 
 In a large cohort of patients we have studied the relationships 
between health outcomes in AS. This analysis showed that 
physical function is independently determined both by the level 
of clinical disease activity and by the degree of spinal mobil-
ity impairment, and that the physical component of HRQoL is 
independently determined by physical function and by the level 
of clinical disease activity. This study also supports the view 
that spinal mobility is hierarchically an intermediate variable 
between structural damage and physical function, while physi-
cal function itself is intermediate between spinal mobility and 
the physical component of SF-36. 
 Combined with a previous analysis of the same cohort show-
ing that spinal mobility impairment in AS is independently 
determined both by irreversible radiographic spinal damage and 
by reversible MRI spinal infl ammation, 24 the results from this 
study allow us to propose a stratifi ed model for health outcomes 
in AS ( fi gure 1 ). This stratifi ed model endorses the ASAS core 
set choice of relevant domains, 2 – 4 and suggests that the generic 
domain HRQoL is highest in hierarchy and that all other domains 
contribute to some extent and independently to HRQoL. 
 The results were largely similar using either ASDAS or 
BASDAI as the measurement tool for clinical disease activity, 
providing further evidence for the validity of the ASDAS as a 
new measure of disease activity in AS. Some discrepancies were 
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were associated with SF-36 MCS to a greater extent than ASDAS. 
However, SF-36 MCS was still independently determined by 
ASDAS when BASFI was deleted as regressor. Erythrocyte sedi-
mentation rate was not tested because it was not available in 
ASSERT, and CRP was not included in the multivariate models 
because its p value was >0.1 in univariate analysis. 
 We have estimated the numerical contribution of each variable 
over the other. This helps to interpret the results of the regres-
sion models by giving them a practical meaning. However, we 
acknowledge that this is a simplifi cation of reality and that the 
relations we have investigated may not be truly linear but rather 
curvilinear, as previously suggested by the correlation between 
damage and mobility which seems to increase with the level of 
damage. 25 
 The results from this study are consistent with a previous 
report 26 showing that physical function in AS is determined by 
the level of patient-reported disease activity and by the level of 
radiographic structural damage, in one of the few longitudinal 
studies addressing health outcomes in AS, with 188 patients 
included in multivariate analysis. Another longitudinal study 27 
looked at 5-year predictors of disability in 212 patients and 
found that higher age, smoking, less frequent back exercise and 
worse social support were associated with a poorer functional 
outcome. However, this study did not adjust for other variables 
potentially associated with function such as structural damage, 
spinal mobility and disease activity. 
 At the cross-sectional level, Wanders  et al 25 showed acceptable 
correlations between measures of spinal mobility and measures 
of structural damage; we have previously shown an independent 
association between spinal mobility, spinal damage and MRI 
infl ammation of the spine 24 ; and Almodovar  et al 28 described 
associations between functional capacity and spinal mobility 
measures. Vesovic-Potic  et al 29 reported a negative independent 
association between the physical functioning domain of SF-36 
and BASFI, while Ozdemir 30 showed that all SF-36 domains 
(except for general health) had signifi cant negative correlations 
with BASDAI and BASFI scores. However, Turan  et al 31 only 
found a signifi cant negative correlation between the general 
health domain and BASDAI, and between the role-emotional 
domain and BASFI. 
 A limitation of our study is its cross-sectional design. Another 
limitation is that it is a clinical trial cohort involving patients 
with severe and active disease. It would be of interest to  validate 
this model in patients with earlier and less severe disease sta-
tus. However, we analysed a large cohort of patients (n=214) 
and explored a large number of outcome measures (from MRI 
infl ammation to HRQoL), adjusting for a number of possible 
contributing and confounding factors. Such a broad and detailed 
analysis has never been reported to date. Furthermore, the items 
used for analysis are generally used in daily clinics and clinical 
studies. We believe that the associations described here are rel-
evant for the management of patients with AS and may serve 
as the background model for future longitudinal studies where 
temporal relationships may be tested. An association does not 
necessarily imply causation, and only longitudinal studies can 
evaluate if a change in an outcome measure translates into a 
subsequent change in the associated measure. 
 In summary, we have studied in detail the relationships 
between several AS outcome measures and propose a strati-
fi ed model for health outcomes in AS. According to this model 
( fi gure 1 ), HRQoL is determined by physical function and disease 
activity, physical function is determined by spinal mobility and 
disease activity, and spinal mobility is determined by structural 
damage and infl ammation of the spine. This model explains a 
large percentage of the variation in the dependent variables, but 
not the entire variation, suggesting that other variables such as 
psychological, social, cultural, ethnic and educational factors 
should also be taken into account in future studies. However, 
the relationships that we describe are indisputable, are consistent 
with the conceptual ‘continuum of outcome measures’ proposed 
by Tennant and McKenna 12 and suggest that, in order to optimise 
HRQoL, both physical function and disease activity should be 
considered major goals in the treatment of AS. They also suggest 
that optimal physical function-preserving therapy should focus 
on improving disease activity and also on maintaining spinal 
mobility which, on its own, requires both the elimination of spi-
nal infl ammation and the prevention of structural damage. This 
stratifi ed model explains why optimal treatment of AS should 
be multimodal, involving non-steroidal anti-infl ammatory drugs 
(NSAIDs) and antitumour necrosis factor (anti-TNF) therapy 
(drugs that have been shown to improve patient-reported dis-
ease activity while, for MRI infl ammation of the spine, the effect 
is only clear for anti-TNF) as well as therapies more specifi cally 
addressing spinal mobility (such as physical therapy) and progres-
sion of structural damage (such as NSAIDs which have shown to 
inhibit structural progression independently of infl ammation). 32 
 As we learn more about how to measure AS, our knowledge 
about the disease improves and we can make better decisions 
on how to assess and treat it. The model we propose is useful 
both for the design and interpretation of clinical trials and also 
for daily clinical practice, and may contribute to guide best prac-
tice in the assessment and treatment of patients with AS. 
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